<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068441</url>
  </required_header>
  <id_info>
    <org_study_id>201904090RINA</org_study_id>
    <nct_id>NCT04068441</nct_id>
  </id_info>
  <brief_title>Measurement for Viral Reservoir and Immune Function in HIV-1-infected Patients Under Antiretroviral Therapy</brief_title>
  <official_title>Measurement for Viral Reservoir and Immune Function in HIV-1-infected Patients Under Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current antiretroviral therapy (ART) is highly effective to suppress plasma viral load to&#xD;
      below the detection limit and to restore the host immunity, thus to prolong the survival of&#xD;
      HIV-1-infected patients remarkably. However, HIV-1 will rebound to pre-treatment levels&#xD;
      within weeks of interruption or irregular medication. The reason why HIV-1 would not be&#xD;
      eradicated by powerful ART can be explained by that the reservoir of latent HIV-1 in resting&#xD;
      CD4 T cells will persistently exist even long-term suppression of plasma viral RNA. Several&#xD;
      therapeutic approaches that aim to prevent or delay viral rebound after treatment&#xD;
      interruption, producing a post-treatment remission or functional cure of HIV-1, are being&#xD;
      investigated. This study is to measure the size of viral reservoir and HIV-1-specific T cell&#xD;
      response in HIV-1-infected patients during ART to help understand the mechanism of HIV-1&#xD;
      persistence, then to help establish a potential policy for functional cure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Proviral DNA levels</measure>
    <time_frame>The changes of baseline proviral DNA at 48 weeks</time_frame>
    <description>quantitative proviral DNA measurement as the marker of HIV reservoir</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Regular treatment</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment interruption</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Regular treatment</arm_group_label>
    <arm_group_label>Treatment interruption</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-1 infected patients receiving antiretroviral treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed HIV-1-infected patients&#xD;
&#xD;
          -  20-50 years old&#xD;
&#xD;
          -  receiving antiretroviral therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious co-morbidity&#xD;
&#xD;
          -  Obvious hepatic or renal dysfunction&#xD;
&#xD;
          -  Receiving immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Szu-Min Hsieh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SZU-MIN Hsieh, M.D.</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>67736</phone_ext>
    <email>hsmaids@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szu-Min Hsieh, M.D.</last_name>
      <phone>886223123456</phone>
      <phone_ext>67736</phone_ext>
      <email>hsmaids@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

